Régis Millet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Régis Millet has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Philippe Chavatte
Univ. Lille, Inserm, CHU Lille, U995 - LIRIC - Lille Inflammation Research International Center, Lille, France
26 shared publications Jean-Pierre Hénichart
Institut de Chimie Pharmaceutique Albert Lespagnol, Université Lille-Nord de France, EA4481, IFR114, 3 Rue du Pr Laguesse, B.P. 83, F-59006 Lille, France
16 shared publicationsRaymond Houssin
16 shared publications- Benoît Rigo
Inserm U995, LIRIC, Université de Lille, CHRU de Lille, Faculté de médecine-Pôle recherche, Place Verdun, F-59045 Lille Cedex, France; Hautes Etudes d'Ingénieur (HEI), Groupe HEI-ISA-ISEN, UCLille, Laboratoire de Pharmacochimie, 13 rue de Toul, F-59046 Lille, France
15 shared publications - Christophe Furman
University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, UMR 1167—RID-AGE—Risk Factors and Molecular Determinants of Aging-Related Diseases, F-59000 Lille, France
13 shared publications - Emmanuelle Lipka
University of Lille, Inserm, CHU De Lille, U1352—BioPrev: Better Aging: From Inflammaging to Prevention Lille France
12 shared publications
Latest Publications
- Open Access
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Chlorophenyl pyrazolone Derivatives as Novel PD-L1-Targeted Inhibitors of the PD-1/PD-L1 Immune Checkpoint
Immune checkpoint inhibitors have emerged as one of the most promising approaches for cancer immunotherapy. Several injectable monoclonal antibodies targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway are used to treat solid tumors. The development of orally active small molecules remains a challenge. In this context, we describe new pyrazolone derivatives bearing a chlorophenyl moiety aimed at targeting PD-L1 dimers. Ten new compounds with nanomolar affinities for PD-L1 were identified and among them, six were able to reactivate proliferation of CTLL-2 cytotoxic T-cells. The best compounds were further characterized for their capacity to modulate PD-L1 dimerization and their interaction with PD-L1 dimers, by microscale thermophoresis and molecular docking, respectively. Novel symmetric bis-pyrazolones with a high affinity for PD-L1 protein were also obtained. The 2,4-dichlorophenylpyrazolone scaffold offers novel perspectives to design PD-L1-targeting agents for the treatment of cancer.
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessChlorophenyl pyrazolone Derivatives as Novel PD-L1-Targeted Inhibitors of the PD-1/PD-L1 Immune Checkpoint
Immune checkpoint inhibitors have emerged as one of the most promising approaches for cancer immunotherapy. Several injectable monoclonal antibodies targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway are used to treat solid tumors. The development of orally active small molecules remains a challenge. In this context, we describe new pyrazolone derivatives bearing a chlorophenyl moiety aimed at targeting PD-L1 dimers. Ten new compounds with nanomolar affinities for PD-L1 were identified and among them, six were able to reactivate proliferation of CTLL-2 cytotoxic T-cells. The best compounds were further characterized for their capacity to modulate PD-L1 dimerization and their interaction with PD-L1 dimers, by microscale thermophoresis and molecular docking, respectively. Novel symmetric bis-pyrazolones with a high affinity for PD-L1 protein were also obtained. The 2,4-dichlorophenylpyrazolone scaffold offers novel perspectives to design PD-L1-targeting agents for the treatment of cancer.
- 27 August 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (19) , 17407-17428
New Potent RIPK2 Inhibitors as a Promising Therapeutic Avenue for Colitis Through the Blockade of NOD Inflammatory Pathways
- 27 August 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (19) , 17407-17428
New Potent RIPK2 Inhibitors as a Promising Therapeutic Avenue for Colitis Through the Blockade of NOD Inflammatory Pathways
- 27 January 2021
- Published by Wiley in Helvetica Chimica Acta
- Vol. 104 (3)
Probing BRD Inhibition Substituent Effects in Bulky Analogues of (+)‐JQ1
A series of bulky organometallic and organic analogues of the bromodomain (BRD) inhibitor (+)‐JQ1 have been prepared. The most potent, N‐[(adamantan‐1‐yl)methyl]‐2‐[(9S)‐7‐(4‐chlorophenyl)‐4,5,13‐trimethyl‐3‐thia‐1,8,11,12‐tetraazatricyclo[8.3.0.02,6]trideca‐2(6),4,7,10,12‐pentaen‐9‐yl]acetamide, 2e, showed excellent potency with an KD=ca. 130 nm vs. BRD4(1) and a ca. 2‐fold selectivity over BRD4(2) (KD=ca. 260 nm). Its binding to the first bromodomain of BRD4 was determined by a protein cocrystal structure.
- 27 January 2021
- Published by Wiley in Helvetica Chimica Acta
- Vol. 104 (3)
Probing BRD Inhibition Substituent Effects in Bulky Analogues of (+)‐JQ1
A series of bulky organometallic and organic analogues of the bromodomain (BRD) inhibitor (+)‐JQ1 have been prepared. The most potent, N‐[(adamantan‐1‐yl)methyl]‐2‐[(9S)‐7‐(4‐chlorophenyl)‐4,5,13‐trimethyl‐3‐thia‐1,8,11,12‐tetraazatricyclo[8.3.0.02,6]trideca‐2(6),4,7,10,12‐pentaen‐9‐yl]acetamide, 2e, showed excellent potency with an KD=ca. 130 nm vs. BRD4(1) and a ca. 2‐fold selectivity over BRD4(2) (KD=ca. 260 nm). Its binding to the first bromodomain of BRD4 was determined by a protein cocrystal structure.
- 17 September 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (5) , 2074-2094
Pyroglutamide-Based P2X7 Receptor Antagonists Targeting Inflammatory Bowel Disease
This report deals with the design, the synthesis and the pharmacological evaluation of pyroglutamide-based P2X7 antagonists. A dozen were shown to possess improved properties, among which inhibition of YO-PRO-1/TO-PRO-3 uptake and IL1β release upon BzATP activation of the receptor and dampening signs of DSS-induced colitis on mice, in comparison with reference antagonist GSK1370319A. Docking study and biological evaluation of synthesized compounds has highlighted new SAR, and low toxicity profiles of pyroglutamides herein described are clues for the finding of a usable h-P2X7 antagonist drug. Such a drug would raise the hope for a cure to many P2X7-dependant pathologies, including inflammatory, neurological and immune diseases.
- 17 September 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (5) , 2074-2094
Pyroglutamide-Based P2X7 Receptor Antagonists Targeting Inflammatory Bowel Disease
This report deals with the design, the synthesis and the pharmacological evaluation of pyroglutamide-based P2X7 antagonists. A dozen were shown to possess improved properties, among which inhibition of YO-PRO-1/TO-PRO-3 uptake and IL1β release upon BzATP activation of the receptor and dampening signs of DSS-induced colitis on mice, in comparison with reference antagonist GSK1370319A. Docking study and biological evaluation of synthesized compounds has highlighted new SAR, and low toxicity profiles of pyroglutamides herein described are clues for the finding of a usable h-P2X7 antagonist drug. Such a drug would raise the hope for a cure to many P2X7-dependant pathologies, including inflammatory, neurological and immune diseases.
- 1 March 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 165, 347-362
Benzo[d]thiazol-2(3H)-ones as new potent selective CB2 agonists with anti-inflammatory properties
- 1 March 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 165, 347-362
Benzo[d]thiazol-2(3H)-ones as new potent selective CB2 agonists with anti-inflammatory properties
- 8 February 2018
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 10 (6) , 631-638
Synthesis and Biological Evaluation of Ferrocene-Based Cannabinoid Receptor 2 Ligands
Ferrocene analogs of known fatty acid amide hydrolase inhibitors and CB2 ligands have been synthesized and characterized spectroscopically and crystallographically. The resulting bio-organometallic isoxazoles were assayed for their effects on CB1 and CB2 receptors as well as on fatty acid amide hydrolase. None had any fatty acid amide hydrolase activity but compound 3, 5-(2-(pentyloxy)phenyl)-N-ferrocenylisoxazole-3-carboxamide, was found to be a potent CB2 ligand (Ki = 32.5 nM).
- 8 February 2018
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 10 (6) , 631-638
Synthesis and Biological Evaluation of Ferrocene-Based Cannabinoid Receptor 2 Ligands
Ferrocene analogs of known fatty acid amide hydrolase inhibitors and CB2 ligands have been synthesized and characterized spectroscopically and crystallographically. The resulting bio-organometallic isoxazoles were assayed for their effects on CB1 and CB2 receptors as well as on fatty acid amide hydrolase. None had any fatty acid amide hydrolase activity but compound 3, 5-(2-(pentyloxy)phenyl)-N-ferrocenylisoxazole-3-carboxamide, was found to be a potent CB2 ligand (Ki = 32.5 nM).
- 1 February 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 146, 68-78
Development of novel oxazolo[5,4-d]pyrimidines as competitive CB2 neutral antagonists based on scaffold hopping
- 1 February 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 146, 68-78
Development of novel oxazolo[5,4-d]pyrimidines as competitive CB2 neutral antagonists based on scaffold hopping
- 14 December 2017
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 83 (1) , 422-430
One- or Two-Step Synthesis of C-8 and N-9 Substituted Purines
A novel and original strategy to obtain rapidly a large diversity of C-8 and N-9 substituted purines was developed. The present procedure describes annulation reactions in one or two steps starting from 5-aminoimidazole-4-carbonitriles 1-8 in moderate to good yields. 8,9-disubstituted-6,9-dihydro-1H-purin-6-ones 9-14, 6-amino-8,9-disubstituted-3,9-dihydro-2H-purin-2-ones 15-20, 8,9-disubstituted-3,9-dihydro-2H-purin-2,6-diamines 21-24 and 6-imino-1-phenyl-8,9-disubstituted-6,9-dihydro-1H-purin-2-(3H)-ones 25-26 were synthesized in one step using formic acid, urea, guanidine carbonate and phenylisocyanate, respectively. Whereas 8,9-disubstituted-9H-purin-6-amines 27-31 and 6-imino-8,9-disubstituted-6,9-dihydro-1H-purin-1-amines 32-33 were obtained in two steps using formamide and hydrazine, respectively.
- 14 December 2017
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 83 (1) , 422-430
One- or Two-Step Synthesis of C-8 and N-9 Substituted Purines
A novel and original strategy to obtain rapidly a large diversity of C-8 and N-9 substituted purines was developed. The present procedure describes annulation reactions in one or two steps starting from 5-aminoimidazole-4-carbonitriles 1-8 in moderate to good yields. 8,9-disubstituted-6,9-dihydro-1H-purin-6-ones 9-14, 6-amino-8,9-disubstituted-3,9-dihydro-2H-purin-2-ones 15-20, 8,9-disubstituted-3,9-dihydro-2H-purin-2,6-diamines 21-24 and 6-imino-1-phenyl-8,9-disubstituted-6,9-dihydro-1H-purin-2-(3H)-ones 25-26 were synthesized in one step using formic acid, urea, guanidine carbonate and phenylisocyanate, respectively. Whereas 8,9-disubstituted-9H-purin-6-amines 27-31 and 6-imino-8,9-disubstituted-6,9-dihydro-1H-purin-1-amines 32-33 were obtained in two steps using formamide and hydrazine, respectively.
- 1 August 2017
- Published by Elsevier in Tetrahedron
- Vol. 73 (35) , 5327-5336
Discovery of highly functionalized scaffolds: Pyrroloimidazolediones as P2X7 receptor antagonists
- 1 August 2017
- Published by Elsevier in Tetrahedron
- Vol. 73 (35) , 5327-5336
Discovery of highly functionalized scaffolds: Pyrroloimidazolediones as P2X7 receptor antagonists
- 1 July 2017
- Published by Elsevier in Journal of Chromatography A
- Vol. 1505, 106-113
Small scale separation of isoxazole structurally related analogues by chiral supercritical fluid chromatography
- 1 July 2017
- Published by Elsevier in Journal of Chromatography A
- Vol. 1505, 106-113
Small scale separation of isoxazole structurally related analogues by chiral supercritical fluid chromatography